News

Novo Nordisk: The Market Has Lost Its Mind
While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Why Novo Nordisk Stock Slipped Today
Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...
Devdiscourse1d
Novo Nordisk Faces Challenges as Copycat Competition Intensifies
Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Novo Nordisk expands legal battle over compounded weight loss drugs
Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.
Marketplace1d
Makers of Wegovy, Zepbound face competition from compounding pharmacies
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.